Thus, an effective personalized cancer therapy by BETi requires not only a thorough understanding of the mechanism of action of the BETs but also a thoughtful consideration of the genetic and epigenetic alterations for each individual cancer, such as the status of TP53. This evidence concerns the gene TP53 and cancer.